ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
All right. Perfect. So welcome, everyone, to the 30th Annual Healthcare Conference of Crédit Suisse. I'm Tiago Fauth. I'm a biotech analyst here at Crédit Suisse. We're joined today by ALX Oncology for a fireside chat. Feel free to e-mail me any questions that you guys want to try to -- I'll try to work those in.
We're joined today by Jaume Pons and Sophia Randolph from ALX Oncology. And basically, we can always start with some brief remarks on some of the highlights of 2021 for ALX Oncology so far. We're going to talk a little bit about the competitive landscape and then dive in to some recent data updates.
But Jaume, you can take it away for a brief intro and I'll -- we'll follow from that.
Yes. So I think that this year has been a good year for us. We have a lot of data coming out, and we have started many Phase II and other trials that we've been in for years. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |